VIDEO: Chemoimmunotherapy regimen extends PFS in prostate cancer subset

CHICAGO — In this video from ASCO Annual Meeting, Andrew J. Armstrong, MD, MS, discusses final results of the phase 2 CHAMP trial evaluating a chemoimmunotherapy regimen in neuroendocrine or aggressive-variant metastatic prostate cancer.“This was an effective regimen, and it’s something that now should be studied in randomized, controlled trials to see if we can improve